KURE

KraneShares MSCI All China Health Care Index ETF

Download KURE Presentation

Download Fact Sheet

Investment Strategy:

KURE seeks to measure the performance of MSCI China All Shares Health Care 10/40 Index. The Index is a free float adjusted market capitalization weighted index designed to track the equity market performance of Chinese companies engaged in the health care sector. The securities in the Index include all types of publicly issued shares of Chinese issuers, which are listed in Mainland China, Hong Kong and United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies.

China Health Care Sector Highlights:

  • China is one of the fastest growing major healthcare markets in the world with a five-year compound annual growth rate of 11%, compared to just 4% in the United States, and -4% in Japan1.
  • China is the second largest healthcare market globally with total healthcare expenditure reaching $558 billion in 20161, a number projected to reach $1.1 trillion by 20202.
  • There is still opportunity for considerable growth in China’s healthcare market with per capita health spending at just $398, compared to an average of over $6,500 for the world’s top eight healthcare markets in terms of per capita expenditure3.
  • China’s aging population, rising incomes and increasing urbanization may provide a sustained catalyst for growth in China’s healthcare sector.

KURE features:

  • Exposure to Chinese companies listed in the Mainland, Hong Kong and United States that are involved in the healthcare industry, specifically: patent and generic pharmaceuticals, hospital administration, biotechnology, medical equipment production, healthcare IT, and traditional Chinese medicine.
  • Exposure to companies that benefit from China’s growing middle class and aging population.
  • Access to leading Chinese pharmaceutical companies which have been recipients of favorable policy and market conditions for research and development and the invention of new medicines and devices.

1.) Major healthcare markets defined as top five global markets by the World Health Organization. Data from the World Health Organization as of 12/31/2016, last updated on 1/8/2019, retrieved on 3/31/2019

2.) International Trade Association, "2016 Top Markets Report Pharmaceuticals, 2016". Retrieved 3/31/2019.

3.) World Health Organization, 2016. Data as of 1/8/2019, retrieved on 3/31/2019.

Fund Details

Data as of 07/02/2020
TickerKURE
Primary ExchangeNYSE
CUSIP500767835
ISINUS5007678353
Net Assets$78,447,407
Total Annual Fund Operating Expense (Gross)0.79%
Total Annual Fund Operating Expense (Net)0.65%*
Inception Date1/31/2018
Distribution FrequencyAnnual

Daily Performance

Data as of 07/02/2020
Premium Discount Chart
NAV
Net Asset Value$31.38 
Daily Change-0.17%
Price
Closing Price$0.00 
Daily Change0.00%

Performance History

Distributions
Cumulative %
Data as of: 06/30/2020
Fund NAVClosing PriceIndex
1 Month17.96%17.76%17.83%
3 Month33.43%33.91%34.25%
6 Month36.24%37.97%37.21%
Since Inception27.80%28.20%29.53%
Avg Annualized %
Data as of quarter end: 06/30/2020
Fund NAVClosing PriceIndex
1 Year56.31%56.42%58.06%
Since Inception10.68% 10.83%11.32%

*Fee waivers are contractual and in effect until 8/01/2020

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.

Top 10 Holdings

Data as of 07/02/2020
Full Holdings .CSV
RankCompany Name% of Net AssetsTickerShares HeldMarket Value($)
1
JIANGSU HENGRU-A
7.29%600276 C1443,6355,721,816
2
WUXI BIOLOGICS CAYMAN INC
6.4%2269 HK274,0005,020,258
3
SINO BIOPHARMACEUTICAL
5.17%1177 HK2,128,5004,059,151
4
SHENZHEN MINDR-A
4.74%300760 C290,5553,721,270
5
CSPC PHARMACEUTI
4.24%1093 HK1,771,2003,322,914
6
ALIBABA HEALTH
4.09%241 HK1,102,0003,206,382
7
WUXI APPTEC CO LTD-A
3.09%603259 C1184,5672,427,448
8
AIER EYE HSPTL-A
2.71%300015 C2355,5422,126,886
9
INNOVENT BIOLOGICS INC
2.68%1801 HK285,5002,103,436
10
CHANGCHUN HIGH-A
2.53%000661 C234,2041,983,669

Holdings are subject to change.